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Introduction
Our understanding of the pathogenesis mechanisms 
leading to lupus has been augmented by the analysis of 
several diﬀ   erent murine models over the past four 
decades. Various mouse models of spontaneous lupus 
have been employed in an eﬀ   ort to understand the 
cellular and genetic mechanisms behind induction of 
systemic lupus erythematosus (SLE). Th   e classic models 
of spontaneous lupus include the F1 hybrid of the New 
Zealand Black (NZB) and New Zealand White (NZW) 
strains, called NZB/W F1, and its derivatives, such as 
NZM2328 and NZM2410, and the MRL/lpr and BXSB/
Yaa strains. Th  e goal of this review is to discuss the 
systemic and local immune responses – as learned from 
the studies employing various mouse model systems – 
that lead to the development of lupus. Th  e cellular and 
molecular mechanisms that contribute to the patho-
genesis of lupus are discussed in the following sections 
and are illustrated in Figure 1.
Systemic autoimmunity in systemic lupus 
erythematosus: handling of self-antigens
Th  e presence of high titers of autoantibodies against 
nuclear antigens is the hallmark of SLE. Whereas there is 
little evidence to indicate whether self-antigens in SLE 
are aberrant in sequence or structure, there is evidence 
that the aberrant handling of self-antigens could facilitate 
lupus pathogenesis. Although apoptotic bodies are 
normally rapidly cleared with the help of the complement 
and other systems, defects in this clearance system could 
lead to the accumulation of apoptotic bodies and their 
prevalence in serum [1]. Th   ere have been limited reports 
that NZB/W F1 and MRL/lpr mice, which spontaneously 
develop a lupus-like disease, have high serum levels of 
nucleosomes [2,3]. Non-autoimmune C3H, BALB/c, and 
C57BL/6 mouse strains, when injected with apoptotic 
bodies, developed serum autoantibodies similar to those 
seen in SLE [4]. Although these studies warrant indepen-
dent conﬁ  rmation, they support the notion that apoptotic 
cells could harbor the immunogens responsible for anti-
nuclear antibody formation. Moreover, mice with defects 
in genes that play an important role in the clearance of 
apoptotic bodies, like DNase I, serum amyloid protein P 
(SAP), sIgM, or tyrosine kinase c-mer, all develop SLE-
like disease with elevated levels of anti-nuclear antibodies 
[5-8]. Th   ese data support the hypothesis that the ineﬃ   -
cient clearance of apoptotic bodies could be one factor 
leading to the development of SLE. Th   e important role of 
the complement system and FcR in the process of 
clearing apoptotic materials has also been recently docu-
mented. Th  us,  C1q-deﬁ  cient mice exhibit impaired inter-
nali  zation of apoptotic cells by peritoneal macro  phages 
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ized by high levels of apoptotic cell bodies [9].
Cells of the adaptive immune system as mediators 
of systemic autoimmunity in systemic lupus 
erythematosus
B lymphocytes in systemic lupus erythematosus
Autoantibodies are major contributors to end organ 
damage as illustrated by the glomerulonephritis asso  ciated 
with anti-nuclear and anti-glomerular antibodies, con-
genital heart block associated with anti-Ro antibody, and 
thrombosis associated with anti-cardiolipin anti  bodies 
[10]. However, B cells can contribute to SLE patho  genesis 
through additional pathways. For example, lupus-prone 
MRL/lpr mice that are made B cell-deﬁ  cient exhibit a 
markedly attenuated disease. Th   ese mice have an absence 
of autoantibodies, as expected, but also display a 
dramatic lack in T-cell activation. Th   is study, by Shlom-
chik and colleagues [11], implied an essential role for B 
cells, but not necessarily autoantibodies, in the patho-
genesis of lupus [11]. In another study, Shlomchik and 
colleagues [12] used MRL/lpr mice expressing a mutant 
immunoglobulin (Ig) that cannot be secreted, thus 
essentially prohibiting autoantibody generation, and 
Figure 1. Pathogenic mechanisms of systemic lupus. Diff  erent subpopulations of immune cells interplay to directly or indirectly regulate other 
subpopulations by releasing diff  erent cytokines and other mediators of infl  ammation, thereby contributing to the progression of the systemic 
disease. The hyperactivated leukocytes as well as the pathogenic autoantibodies and immune complexes resulting from the systemic disease 
ultimately play an important role in local autoimmunity and end organ disease within target organs like the kidneys. Ab, antibody; BAFF, B-cell 
activation factor; DC, dendritic cell; IC, immune complex; IFN-I, interferon-I; IL-10, interleukin-10; MΦ, macrophage; MHC, major histocompatibility 
complex; self-Ag, self-antigen; TCR, T-cell receptor; TGF-β, transforming growth factor-beta.
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Page 2 of 9showed that those mice still developed nephritis and 
vasculitis with associated T-cell activation. Th  at study 
convincingly showed that B cells may contribute to the 
development of lupus in ways that are independent of 
autoantibodies. Th   e additional role of B cells as antigen-
presenting cells that mediate T-cell activation in lupus 
comes from MRL/lpr mice studies showing that B-cell 
deﬁ   ciency leads to reduced CD4+ and CD8+ T-cell 
activation [13].
Besides secreting proinﬂ  ammatory cytokines like inter-
leukin-6 (IL-6) and interferon-gamma (IFN-γ), B cells 
may secrete IL-10, which has an anti-inﬂ  ammatory func-
tion. Th  erefore, B cells that secrete IL-10 (or B10 cells) 
have been called regulatory B cells and were ﬁ  rst reported 
in B10.PL mice in which IL-10-producing B cells were 
found to regulate the severity of experimental auto-
immune encephalitis [14]. In murine lupus, IL-10 deﬁ  ci-
ency was found to contribute to more severe disease with 
an increase in Th  1 cytokine levels [15]. A recent study 
using CD19−/− NZB/W mice reported that B10 cells could 
induce expansion of regulatory T cells, a subset of T cells 
with immunosuppressive function [16]. However, data 
from human lupus reveal a diﬀ  erent facet of IL-10. In the 
case of human SLE, studies suggest that IL-10 promotes 
rather than inhibits lupus [17]. A better understanding of 
the role of IL-10-producing B cells and the mechanism of 
action of IL-10 is required to explain the diﬀ  erences 
between the murine and human data.
Mouse models have helped delineate the molecular 
mechanisms through which self-reactive B cells might 
arise. Sle1 is a lupus susceptibility locus derived from the 
NZM2410 mouse strain. Using Sle1 congenic C57Bl6 
mice, Kumar and colleagues [18] reported that the auto-
immune-associated variant of the Ly108 gene, a member 
of the SLAM family of immune cell receptors which lies 
within the Sle1 locus, leads to loss of B-cell tolerance 
because of impaired negative selection of autoreactive B 
cells at the immature B-cell stage. On the other hand, 
increased B-cell signaling, especially in the case of mature 
peripheral B cells, has been implicated in the patho-
genesis of humoral autoimmunity. Mice that are deﬁ  cient 
in various inhibitory molecules that dampen B-cell 
receptor (BCR) signaling, such as SHP-1 [19], Lyn [20], or 
FcγRIIb [21], develop systemic autoimmunity. Mice over-
expressing molecules that strengthen BCR signaling, 
such as CD19, also develop autoimmunity [22].
Recent studies have implicated a class of immune 
system receptors called Toll-like receptors (TLRs) in the 
synergistic activation of B cells by BCR and TLR 
signaling. Simultaneous engagement of BCRs that are 
speciﬁ  c for DNA by nuclear antigens that are abundant in 
apoptotic material and TLR9 on B cells causes activation 
of both BCR and TLR signaling pathways [23]. In the 
NZB/W and MRL/lpr mouse models of lupus, activation 
of TLR9 with a synthetic DNA ligand causes accelerated 
nephritis with increased anti-DNA antibody levels [24]. 
On the other hand, TLR9-deﬁ  cient autoimmune mouse 
models exhibit lower levels of anti-double-stranded DNA 
(anti-dsDNA) and anti-chromatin antibody [25]. Similarly, 
B cells possessing BCRs speciﬁ   c for RNA could be 
synergistically activated by BCR and TLR7 signaling [26]. 
Th  ese  ﬁ  ndings were supported by research in the BXSB 
mouse model of lupus. Duplication of the TLR7 gene in 
the Yaa lupus susceptibility locus leads to increased gene 
dosage eﬀ  ects that contribute to the lupus-like phenotype 
seen in this model [27].
Defects that may lead to increased survival of auto-
reactive B cells have also been found to contribute to the 
development of autoimmunity. B-cell activation factor 
(BAFF) is a major B-cell survival factor that func  tions 
particularly at the transitional B-cell stage. BAFF trans-
genic mice develop a lupus-like disease with expansion of 
the peripheral B-cell pool and heightened production of 
autoantibodies [28]. Increased BAFF levels are thought to 
infringe the negative selection checkpoint at the T1 
transitional stage, thereby allowing the survival and 
maturation of autoreactive B cells in the periphery and 
their participation in the germinal center reaction. Th  ese 
ﬁ  ndings are supported by the observations that lupus-
prone mice exhibit elevated serum BAFF levels and that 
administration of TACI-Ig, which acts as a soluble recep-
tor for BAFF, is eﬀ  ective in treating murine lupus [29].
T lymphocytes in systemic lupus erythematosus
Th  e obligatory role of T cells in lupus pathogenesis has 
been demonstrated by using several genetically engi  neered 
mouse models [30]. Lupus T cells are likely to contribute 
to disease through contact-dependent mechanisms 
(mediated by CD40L:CD40, OX40L:OX40, and so on) as 
well as released cytokines [30]. One important cytokine 
secreted by the Th   1 cells is IFN-γ, which plays a pivotal 
role in the production of pathogenic isotypes of anti-
nuclear autoantibodies in murine lupus models. 
Expression of IFN-γ in the skin of transgenic mice leads 
to the production of anti-DNA and anti-Sm auto-
antibodies [31]. A deﬁ  ciency of IFN-γ in MRL/lpr and 
NZB/W lupus-prone mice leads to reduced anti-DNA 
antibody levels [32,33]. In support of these ﬁ  ndings, 
blocking the IFN-γ receptor with monoclonal antibodies 
or soluble IFN-γ receptor reduces disease activity in 
lupus-prone mice [34,35].
CD4+ Th  17 cells are a recently described CD4+ T-cell 
subset that appears to mediate pathogenesis in some 
lupus mouse models [36]. However, it has become clear 
that the contribution of Th   17 cells to autoimmunity is far 
more complex, depending on the disease and mouse 
model [37]. Studies in patients with SLE or related 
diseases have demonstrated that Th  17 cells may have a 
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[38]. Given the heterogeneity of the disease, it may be 
possible that Th   17 cells play a role in lupus pathogenesis 
in a genetically deﬁ  ned subset of subjects or in particular 
end organ manifestations and that anti-IL-17 therapy 
may be helpful speciﬁ  cally in those patients. In addition, 
the regulatory T cell subset appears to modulate the 
breakdown of T-cell tolerance in lupus [39]. Clearly, we 
need to gain a better understanding of how pathogenic T 
cells (Th   17 cells) and regulatory T cells, perhaps in yin-
yang fashion, dictate disease activity in lupus.
Innate immune cells as mediators of systemic 
autoimmunity in systemic lupus erythematosus
Th   e important role of the innate immune system in SLE 
pathogenesis has only recently been appreciated. 
Described below are the possible roles played by three 
key cell types in the innate immune system.
Monocytes/macrophages
Monocytes/macrophages from patients with lupus have 
been found to have a reduced capacity to phagocytose 
apoptotic materials [40], and their numbers were reduced 
in the inﬂ   ammatory exudates from patients with SLE 
[41]. It was postulated, on the basis of those studies, that 
the defective phagocytosis of monocytes/macrophages 
contributed to ineﬃ   cient clearing of apoptotic materials, 
leading to autoimmunity [42], a notion that is supported 
by mice lacking the myeloid cell receptors, Tyro3, Axl, 
and Mer receptor tyrosine kinases [43,44]. Whereas 
c-mer knockout mice exhibited increased anti-dsDNA 
auto  antibody levels without any signiﬁ  cant renal patho-
logy [43], Tyro3/Axl/Mer triple-knockout mice exhibited 
high levels of autoantibodies along with multiple end 
organ involvement [44].
Monocytes/macrophages can contribute to disease in 
another important way: through the elaboration of pro-
inﬂ  ammatory cytokines and chemokines. Th  is is illus-
trated by macrophages from B6.Sle3 congenic mice, in 
which Sle3 is a lupus susceptibility locus derived from the 
NZM2410 lupus-prone strain [45]. Th   ese murine studies 
showed that monocytes/macrophages in lupus probably 
have defects beyond abnormal phagocytosis and that 
these cells may take part in aberrant regulation of the 
immune system. A study by Kilmon and colleagues [46] 
demonstrated that macrophages regulate B-cell tolerance 
by secreting regulatory factors like IL-6 and CD40L and 
that macrophages from lupus-prone MRL/lpr mice are 
less capable of repressing Ig secretion coincident with 
reduced secretion of these repressive factors. Collectively, 
these ﬁ   ndings implicate a more signiﬁ   cant role for 
monocytes/macrophages in the pathogenesis of lupus, 
but further studies in patients with SLE are necessary to 
substantiate these ﬁ  ndings.
Polymorphonuclear cells in systemic lupus erythematosus
A neutrophil-speciﬁ   c gene expression signature was 
reported to correlate positively with SLE disease activity 
in patients with SLE [47], suggesting that these cells may 
play an important role in SLE pathogenesis. Th  e exact 
mechanism by which this occurs is not yet clear. 
However, a recent study demonstrated that neutrophil 
extracellular traps, which are networks of DNA, histones, 
and neutrophil proteins that function primarily to trap 
microorganisms, may be involved in SLE pathogenesis, 
possibly by generating autoantigens and serving as adju-
vants [48]. Th   e role of neutrophils in murine lupus, unlike 
that in human lupus, is poorly studied.
Dendritic cells in systemic lupus erythematosus
Studies in mouse models have been pivotal in deter  min-
ing the role that dendritic cells (DCs) play in the patho-
genesis of lupus. One of the earliest ﬁ  ndings implicating 
the putative role of DCs in the breakdown of tolerance 
was that transferring DCs from normal donor mice to 
normal recipient mice could cause loss of tolerance in the 
host, leading to the appearance of anti-DNA and anti-
cardiolipin autoantibodies [49]. A study by Chen and 
colleagues [50] showed that mice with defective DC 
apoptosis accumulated large numbers of DCs and 
exhibited chronic lymphocyte activation and systemic 
autoimmunity.
Other studies using murine models have helped in 
identifying the genetic loci responsible for imparting the 
abnormal phenotypes seen in DCs from lupus-prone 
mice. One such locus is Sle3, which is a lupus suscepti-
bility locus derived from the NZM2410 strain of lupus-
prone mice. C57BL/6 (B6) mice congenic for Sle3 develop 
moderate glomerulonephritis along with modest levels of 
anti-nuclear antibodies [51]. Moreover, the DCs from 
B6.Sle3 congenics are less susceptible to apoptosis, have a 
more mature phenotype, and are more proinﬂ  am  matory. 
Th   ey are also more eﬃ   cient in stimulating T cells in vitro 
and eliciting autoantibodies in vivo compared with DCs 
from normal B6 mice [45]. Th  ese studies provided 
insights into genetic factors and immune mechanisms 
related to abnormal DC activation in murine lupus.
Studies have also shown that DCs play an important 
role in SLE pathogenesis by secreting potent pro  inﬂ  am-
matory cytokines, such as type I IFNs (IFN-α) [52]. 
Immune complexes (ICs) puriﬁ  ed from sera of patients 
with SLE were found to stimulate plasmacytoid DCs 
(pDCs) to produce IFN-α [53]. Later studies revealed a 
possible role of TLRs as potent inducers of IFN-α 
production by activated pDCs in lupus. IFN-α secreted 
by activated pDCs was found to directly inﬂ  uence B cells 
to produce antibodies of the IgG subclass against soluble 
autoantigens in mice [54]. Th   is cytokine also upregulated 
BAFF expression by monocytes and mature DCs, which 
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their diﬀ   erentiation into plasmablasts [55]. Together, 
these reciprocal events lead to a pathogenic cycle, in 
which both the innate and adaptive immune systems 
cooperate and feedback upon each other, eventually 
leading to high titers of autoantibodies.
Local autoimmunity in systemic lupus 
erythematosus
SLE is an autoimmune disease that aﬀ  ects multiple organ 
systems, including the kidney, skin, heart, lung, and 
hematopoietic and nervous systems. As reviewed below 
and illustrated in Figure 1, the players mediating local 
autoimmunity and renal disease in lupus can be classiﬁ  ed 
broadly as (a) ICs and inﬁ  ltrating cells of hematological 
origin and (b) resident cells of the kidneys.
Role of immune complexes and inﬁ   ltrating cells of 
hematological origin in lupus nephritis{Level 2 heading}
Anti-DNA and DNA ICs were the ﬁ  rst ICs isolated 
from kidney elutes of patients with SLE and mouse 
models [56]. Intraperitoneal injection of human and 
murine anti-DNA antibodies was found to trigger lupus-
like kidney disease [57], establishing a direct role of these 
antibodies in the pathogenesis of lupus nephritis. 
Similarly, transgenic overexpression of Ig anti-DNA anti-
bodies in mouse models can lead to renal pathology 
similar to that seen in human lupus nephritis, highlight-
ing a causal role for autoantibodies in the development of 
lupus nephritis [58].
Various mechanisms have been proposed to explain 
how anti-DNA antibodies may lead to renal disease in 
lupus [59]. Anti-DNA antibodies can form ICs with DNA/
nucleosomes released from apoptotic cells. Eventually, 
ICs become deposited in the kidney, leading to the 
initiation of a local inﬂ  ammatory response through FcγR- 
or complement-mediated mechanisms or both. Alter-
nately, anti-DNA antibodies may bind to DNA/nucleo-
somes that have been trapped or ‘planted’ in the kidney 
glomerulus. A third mechanism suggests possible cross-
reactivity between anti-DNA antibodies and local renal 
antigens like laminin, alpha-actinin, and heparan sulfate 
[60].
Other studies have shown that anti-DNA antibodies 
are not an absolute requirement for development of SLE. 
NZM2328.Lc4 mice exhibit lupus-like disease with 
glomerular IC deposits and eventually develop fatal lupus 
nephritis. Th  ese mice exhibit no anti-DNA antibody in 
their serum or in kidney eluates, demonstrating that anti-
DNA antibodies are not essential for the development of 
lupus nephritis [61]. Antibodies obtained from the 
kidney elutes of these mice reacted with various renal 
antigens, but none was speciﬁ  c for dsDNA [62]. Another 
study eluted Igs from renal tissues obtained from patients 
with lupus at autopsy and screened the Igs against a panel 
of 14 diﬀ  erent antigens, which included dsDNA, chroma-
tin, Sm, SSA, SSB, and histones [63]. Th   ese authors found 
that only 0.3% to 41.3% of total kidney-eluted IgG reacted 
with these antigens. Th  erefore, a vast majority of renal 
antibodies bind to yet-unknown antigens. In support of 
this idea, a study using a glomerular proteome array 
showed that serum from lupus mice and patients reacts 
with multiple nuclear and matrix-derived autoantigens 
[64].
Role of lymphoid cells in lupus nephritis
Lymphoid aggregates with T cells and B cells have been 
observed within the kidneys aﬄ   icted by lupus nephritis, 
although their intrarenal roles remain to be fully appre-
ciated. T cells also play a major role in pathogenesis of 
SLE. Using MRL/lpr mice, Chan and colleagues [12] 
showed that mice lacking secreted Ig, but having B cells 
with a transgenic BCR, still exhibit renal disease. In 
another study, Schiﬀ  er and colleagues [65] treated NZB/
W F1 mice that had established nephritis with CTLA4Ig; 
this led to disease remission with a signiﬁ  cant delay in 
mortality. Using a transgenic mouse model system, 
Heymann and colleagues [66] demonstrated that both 
cytotoxic T (Tc) cells and Th   cells have direct roles in 
glomerulonephritis. Th  e authors used transgenic mice 
expressing the model antigens ovalbumin and hen egg 
lysozyme in glomerular epithelial cells called podocytes.   
Co-injection of ovalbumin-speciﬁ  c trans  genic CD8+ Tc 
and CD4+ Th   cells into these mice resulted in peri-
glomerular mononuclear inﬁ  ltrates and inﬂ  ammation of 
parietal epithelial cells, similar to lesions frequently 
observed in human chronic glomerulo  nephritis. Th  e 
ovalbumin-speciﬁ  c  CD8+ Tc cells were found to be 
activated and expanded in the renal lymph nodes, and 
the activation of T cells in turn could be prevented by 
depletion of DCs. Crosstalk between tubulointerstitial 
DCs and Th   cells resulted in intrarenal cytokine and 
chemokine production and in recruitment of more Tc 
cells, monocyte-derived DCs, and macrophages. Th  at 
study was the ﬁ   rst direct evidence that glomerular 
antigen-speciﬁ  c Tc and Th   cells can induce glomerulo-
nephritis in a process regulated by DCs. Although similar 
studies in the context of lupus nephritis are eagerly 
awaited, the above studies suggest that type IV hyper-
sensitivity-driven mechanisms are likely to be important 
in mediating autoimmune nephritis.
Kidneys of nephritic NZM2328 mice show high levels 
of expression of Th   1-type cytokines like IFN-γ and IL-12 
[67]. Administration of IFN-γ, a Th   1 cytokine, to NZB/W 
F1 mice exacerbates disease, whereas the deﬁ  ciency of 
IFN-γ in MRL/lpr mice ameliorates nephritis [32,34]. 
Similarly, inhibition of IL-18, a cytokine that induces 
IFN-γ and other Th  1 cytokines, was found to cause a 
signiﬁ  cant reduction in lymphoproliferation and IFN-γ 
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[68]. Th  ese studies reinforce the concept that type IV 
hypersensitivity reactions may also contribute to lupus 
nephritis.
Other studies have shown a possible role for IL-4, a 
Th   2-type cytokine, in glomerulosclerosis in which trans-
genic overexpression of IL-4 was found to facilitate 
glomerulo  sclerosis [69]. In various studies, IL-4 was 
found to have a direct eﬀ  ect on ﬁ  broblast proliferation, 
collagen gene expression, and collagen synthesis [70]. 
Moreover, inhibition of IL-4 signaling in various lupus-
prone mouse models was found to protect mice from 
developing advanced nephritis in the presence of anti-
DNA antibody and inﬁ  ltrating inﬂ  ammatory cells [32]. 
Th   erefore, IL-4 appears to play a pivotal role in the patho-
genesis of glomerulosclerosis and chronic renal ﬁ  brosis 
in lupus by acting directly upon resident renal cells.
Role of myeloid cells in lupus nephritis
Inﬁ  ltration of DCs in the glomeruli and tubulointerstitial 
spaces of the kidneys has been reported in various 
murine models of nephritis, including NZB/W F1 [67], 
anti-glomerular basement membrane (anti-GBM) [71], 
and mice engineered to express a foreign antigen on 
podocytes [66]. DCs may promote lupus nephritis by 
several mechanisms. One mechanism may be through 
migration of DCs to local lymph nodes and presentation 
of renal antigens to autoreactive lymphocytes in the local 
lymph nodes, thereby initiating an autoimmune response 
against renal autoantigens [72]. DCs may also secrete a 
variety of diﬀ  erent proinﬂ  ammatory and proﬁ  brotic cyto-
kines like IL-6, IL-1, IL-18, IFN-α, tumor necrosis factor-
alpha (TNF-α), and transforming growth factor-beta to 
promote renal inﬂ   ammation and ﬁ   brosis [73]. Despite 
these possibilities, we do not currently understand the 
degree to which intrarenal DCs are important for lupus 
pathogenesis or the exact mechanisms through which 
they operate.
Similar to DCs, macrophages are recruited to the 
nephritic kidneys of patients with SLE and lupus-prone 
mice [74,75] and inﬂ   uence the progression of lupus 
nephritis. In a study using poly(I:C)-induced lupus 
nephritis in NZB/W mice, proliferative glomerulo-
nephritis was found to be associated with renal-
inﬁ   ltrating macrophages and renal expression of IFN-
inducible genes, matrix metalloproteinases (MMPs), and 
growth factors [76]. Glomerular crescent formation and 
renal MMP and growth factor expression were dependent 
on renal macrophages that expressed IL-10, MMPs, 
osteopontin, and various growth factors, includ  ing 
platelet-derived growth factor-C (PDGF-C) and heparin-
binding epidermal growth factor-like growth factor (HB-
EGF) [76]. Th  ese  ﬁ  ndings accord a potentially important 
role for macrophages as mediators of aggressive nephritis 
in lupus by driving the expression of various cytokines 
and growth factors in the kidney. Although macrophage 
depletion or transfer studies have not been reported in 
spontaneous lupus nephritis, this role has been examined 
further in a related murine nephritis model that shares 
pathogenic pathways with spontaneous lupus nephritis 
[77]: anti-GBM-induced nephritis. In the latter model, 
depletion and adoptive transfer studies have demon-
strated a critical role for macrophages in the pathogenesis 
of nephritis [78,79].
By implanting renal tubular epithelial cells genetically 
modiﬁ  ed to produce colony-stimulating factor-1 (CSF-1) 
under the renal capsule of MRL/lpr mice, Kelley and 
colleagues [80] showed that CSF-1 and TNF-α released 
by tubular epithelial cells were responsible for promoting 
renal pathology by fostering macrophage accumulation. 
In a study using NZB/W lupus-prone mice, Schiﬀ  er and 
colleagues [75] identiﬁ  ed an activated type II macrophage 
population as a key marker for proteinuria onset and 
disease remission and suggested that therapy for lupus 
nephritis include strategies that prevent both activation 
of monocytes and their migration to the kidney.
Neutrophils, another myeloid cell subtype, have also 
been shown to inﬁ  ltrate nephritic kidneys and contribute 
to the pathogenesis of experimental nephritis [81], 
although their role in lupus nephritis is less well deﬁ  ned. 
Neutrophils release various proinﬂ  ammatory cytokines 
[82] as well as proteases and reactive oxygen species that 
lead to acute inﬂ  ammation and renal tissue injury [83]. 
Further studies in murine models are clearly warranted.
Role of resident renal cells in lupus nephritis
It is clear that many intrinsic renal cells, including podo-
cytes and tubular epithelial cells, have the capacity to co-
stimulate intrarenal T cells via ICAM-I, MHC-II, B-7,   
and/or CD40-mediated mechanisms [84-86] or by releas-
ing pathogenic cytokines [87]. However, the extent to 
which these intrarenal co-stimulatory mechanisms and 
cytokines are operative in spontaneous lupus nephritis 
remains unknown. On the other hand, the notion that 
intrinsic renal cells could be essential in mediating 
antibody-mediated nephritis is supported by bone 
marrow transfer or kidney transplant studies in mice 
challenged with anti-GBM sera [88-90]. Th  ese studies 
have deﬁ   ned the roles of MHC-II, INF-α, and Fn14 
expression on intrinsic renal cells in mediating nephritis. 
Overall, we have a very limited understanding of the role 
that intrinsic renal cells play in spontaneous lupus 
nephritis.
Conclusions
As discussed in this review, mouse models have proven 
to be indispensable for understanding the immunological 
and molecular basis of systemic autoimmunity in lupus. 
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autoimmunity in target organs and the responses that 
target organs play are equally important in disease 
pathogenesis. Murine models are also proving to be 
instrumental in helping us unravel the intricate 
mechanisms that underlie the end organ responses in 
lupus, although the speciﬁ  c roles of various cell types 
warrant systematic investigation. Mouse models have 
also enhanced our understanding of the respective roles 
of various cells and molecules in the innate immune 
system and the interplay between the innate and adaptive 
immune systems in lupus pathogenesis. Th  e challenge 
ahead is to better deﬁ   ne the cellular and molecular 
players orchestrating lupus and to translate our improved 
understanding of lupus pathogenesis into better 
rationalized therapeutics targeting selected cells or 
molecules (or both) that facilitate lupus.
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